Xenikos B.V.

📍 Nijmegen, Netherlands🗓 Founded 2009👥 3 employees💰 Last funded May 2018
Biotechnology Research🌐 xenikos.com
Website LinkedIn
Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2009
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Xenikos B.V.?
Xenikos B.V. has 1 investors on record on gritt.io and 1 late-stage investors.
When did Xenikos B.V. last raise funding?
The most recent investment in Xenikos B.V. recorded on gritt.io was in May 2018.
When was Xenikos B.V. founded?
Xenikos B.V. was founded in 2009.
What industry is Xenikos B.V. in?
Xenikos B.V. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Xenikos B.V. based?
Xenikos B.V. is headquartered in Nijmegen, Netherlands.